Topka S, Vijai J, Walsh MF, Jacobs L, Maria A, Villano D, Gaddam P, Wu G, McGee RB, Quinn E, Inaba H, Hartford C, Pui C-H, Pappo A, Edmonson M, Zhang MY, Stepensky P, Steinherz P, Schrader K, Lincoln A, Bussel J, Lipkin SM, Goldgur Y, Harit M, Stadler ZK, Mullighan C, Weintraub M, Shimamura A, Zhang J, Downing JR, Nichols KE, Offit K.
Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. PLoS Genet. 2015;11(6):e1005262.
Bergstrom KSB, Morampudi V, Chan JM, Bhinder G, Lau J, Yang H, Ma C, Huang T, Ryz N, Sham HPan, Zarepour M, Zaph C, Artis D, Nair M, Vallance BA.
Goblet Cell Derived RELM-β Recruits CD4+ T Cells during Infectious Colitis to Promote Protective Intestinal Epithelial Cell Proliferation. PLoS Pathog. 2015;11(8):e1005108.
Bergstrom KSB, Morampudi V, Chan JM, Bhinder G, Lau J, Yang H, Ma C, Huang T, Ryz N, Sham HPan, Zarepour M, Zaph C, Artis D, Nair M, Vallance BA.
Goblet Cell Derived RELM-β Recruits CD4+ T Cells during Infectious Colitis to Promote Protective Intestinal Epithelial Cell Proliferation. PLoS Pathog. 2015;11(8):e1005108.
Brestoff JR, Kim BS, Saenz SA, Stine RR, Monticelli LA, Sonnenberg GF, Thome JJ, Farber DL, Lutfy K, Seale P, Artis D.
Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature. 2015;519(7542):242-6.
Chen L, He Z, Slinger E, Bongers G, T Lapenda L, Pacer ME, Jiao J, Beltrao MF, Soto AJ, Harpaz N, Gordon RE, Ochando JC, Oukka M, Iuga AC, Chensue SW, Blander JM, Furtado GC, Lira SA.
IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology. Mucosal Immunol. 2015;8(2):390-402.
Chen L, He Z, Slinger E, Bongers G, T Lapenda L, Pacer ME, Jiao J, Beltrao MF, Soto AJ, Harpaz N, Gordon RE, Ochando JC, Oukka M, Iuga AC, Chensue SW, Blander JM, Furtado GC, Lira SA.
IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology. Mucosal Immunol. 2015;8(2):390-402.
Chen L, He Z, Slinger E, Bongers G, T Lapenda L, Pacer ME, Jiao J, Beltrao MF, Soto AJ, Harpaz N, Gordon RE, Ochando JC, Oukka M, Iuga AC, Chensue SW, Blander JM, Furtado GC, Lira SA.
IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology. Mucosal Immunol. 2015;8(2):390-402.
Hepworth MR, Fung TC, Masur SH, Kelsen JR, McConnell FM, Dubrot J, Withers DR, Hugues S, Farrar MA, Reith W, Eberl G, Baldassano RN, Laufer TM, Elson CO, Sonnenberg GF.
Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4⁺ T cells. Science. 2015;348(6238):1031-5.
Tang J, Iliev ID, Brown J, Underhill DM, Funari VA.
Mycobiome: Approaches to analysis of intestinal fungi. J Immunol Methods. 2015;421:112-21.
Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen W-P, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LMaria, Szabo E, Rosenberg DW, Lipkin SM.
A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum. Cancer Prev Res (Phila). 2015;8(3):222-30.
Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen W-P, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LMaria, Szabo E, Rosenberg DW, Lipkin SM.
A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum. Cancer Prev Res (Phila). 2015;8(3):222-30.
Hirten R, Longman RS, Bosworth BP, Steinlauf A, Scherl E.
Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease. Am J Gastroenterol. 2015;110(12):1737-8.